Difficulty: Medium
Average Score: 78%
Practice
The physician plans to prescribe trastuzumab (Herceptin) for the patient with breast cancer. What testing will the physician order before prescribing this medication?
Correct answer
A
Rationale
Rationale:
The correct answer is A) HER2 protein levels. Trastuzumab (Herceptin) is a targeted therapy used in the treatment of breast cancer, specifically in patients who overexpress the HER2 protein. Before prescribing trastuzumab, it is crucial to test for HER2 protein levels to determine if the patient is a suitable candidate for this medication.
Option B) BRCA2 gene mutation and C) BRCA1 gene mutation are related to genetic mutations that increase the risk of developing breast cancer but are not directly relevant to the decision of prescribing trastuzumab. These genetic tests are more commonly used in assessing the risk of developing breast cancer rather than guiding treatment decisions.
Option D) Stage II cancer identification is important for determining the extent of the disease and planning the overall treatment strategy. However, it does not specifically inform the decision to prescribe trastuzumab based on HER2 protein expression.
In an educational context, understanding the rationale behind pre-treatment testing for medications like trastuzumab enhances students' knowledge of personalized medicine and targeted therapies in oncology. It emphasizes the importance of conducting appropriate tests to tailor treatment plans to individual patients, ultimately improving outcomes and minimizing adverse effects.
The correct answer is A) HER2 protein levels. Trastuzumab (Herceptin) is a targeted therapy used in the treatment of breast cancer, specifically in patients who overexpress the HER2 protein. Before prescribing trastuzumab, it is crucial to test for HER2 protein levels to determine if the patient is a suitable candidate for this medication.
Option B) BRCA2 gene mutation and C) BRCA1 gene mutation are related to genetic mutations that increase the risk of developing breast cancer but are not directly relevant to the decision of prescribing trastuzumab. These genetic tests are more commonly used in assessing the risk of developing breast cancer rather than guiding treatment decisions.
Option D) Stage II cancer identification is important for determining the extent of the disease and planning the overall treatment strategy. However, it does not specifically inform the decision to prescribe trastuzumab based on HER2 protein expression.
In an educational context, understanding the rationale behind pre-treatment testing for medications like trastuzumab enhances students' knowledge of personalized medicine and targeted therapies in oncology. It emphasizes the importance of conducting appropriate tests to tailor treatment plans to individual patients, ultimately improving outcomes and minimizing adverse effects.